KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$14.47 USD
-0.92 (-5.98%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.49 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KALV 14.47 -0.92(-5.98%)
Will KALV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KALV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALV
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
KALV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
Here's Why You Should Invest in Alpine (ALPN) Stock Now
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
Other News for KALV
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
KalVista begins trial for sebetralstat in children with hereditary angioedema
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch